...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >The effect of a switch to ziprasidone in an adult population with autistic disorder: chart review of naturalistic, open-label treatment.
【24h】

The effect of a switch to ziprasidone in an adult population with autistic disorder: chart review of naturalistic, open-label treatment.

机译：在自闭症成年人群中改用齐拉西酮的影响：自然，开放标签治疗的图表审查。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: The present investigation retrospectively assessed the effect of an open-label switch to ziprasidone from other atypical antipsychotics on behavior, weight, and lipid levels in an adult population with autistic disorder. METHOD: We conducted a chart review of 10 adults (mean +/- SD age = 43.8 +/- 6.0 years) with DSM-IV autistic disorder who were switched from other atypical antipsychotics to ziprasidone, primarily due to weight gain, but other reasons included hypercholesterolemia, maladaptive behaviors, drowsiness, and depression. They had been treated with ziprasidone for at least 6 months. Our review focused on frequency of maladaptive behaviors, weight, and lipid levels. RESULTS: The mean +/- SD daily dose of ziprasidone was 128 +/- 41 mg, and all 10 patients continued with this same treatment after completion of the 6-month trial. Seven patients were found to have an improvement or no change in their maladaptive behavior. Eight patients (80%) lost weight (mean change = -13.1 +/- 7.0 lb[-5.9 +/- 3.2 kg]), 4 (80%) of 5 patients had a decrease in total cholesterol level, and 3 (60%) of 5 had a decrease in triglyceride levels. Data on lipid levels were available for 5 of the 10 patients. Behavioral activation was not noted in this population. There were no significant adverse effects associated with ziprasidone. CONCLUSION: In adults with autism, a switch to ziprasidone from other atypical antipsychotics appears to have the potential for maintaining beneficial effect on behavior while improving major health indices including weight and lipid levels.
机译：背景：本研究回顾性地评估了自闭症患者从其他非典型抗精神病药物转用齐拉西酮的开放标签对行为，体重和血脂水平的影响。方法：我们对10名DSM-IV自闭症患者（平均体重减轻，但由于其他原因而从其他非典型抗精神病药物转为使用齐拉西酮的成年人）进行了图表回顾（平均+/- SD年龄= 43.8 +/- 6.0岁）包括高胆固醇血症，适应不良行为，嗜睡和抑郁。他们已接受齐拉西酮治疗至少6个月。我们的审查集中在适应不良行为的频率，体重和脂质水平。结果：齐拉西酮的平均+/- SD日剂量为128 +/- 41 mg，所有10例患者在完成为期6个月的试验后继续接受相同的治疗。发现七名患者的适应不良行为有所改善或没有改变。八名患者（80％）减轻了体重（平均改变= -13.1 +/- 7.0磅[-5.9 +/- 3.2千克]），五名患者中有四名（80％）的总胆固醇水平降低，三名（60％） 5％）的甘油三酯水平降低。 10位患者中有5位的血脂水平数据可用。在该人群中未发现行为激活。齐拉西酮无明显不良反应。结论：在患有自闭症的成年人中，从其他非典型抗精神病药转向齐拉西酮似乎有可能对行为产生有益影响，同时改善包括体重和血脂水平在内的主要健康指数。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号